PnPP-19 Peptide as a Novel Drug Candidate for Topical Glaucoma Therapy Through Nitric Oxide Release
PnPP-19 Peptide Restores Erectile Function in Hypertensive and Diabetic Animals Through Intravenous and Topical Administration.
Corpus cavernosum relaxation was evaluated using cavernous strips from male spontaneous hypertensive rats (SHR) and from streptozotocin (STZ)-diabetic mice contracted with phenylephrine and submitted to electrical field stimulation before and after incubation with PnPP-19 (10-8 mol/L, 10 minutes) or vehicle. This procedure was also used to determine cGMP/nitric oxide levels, at 8 Hz and to check the effect of PnPP-19 with sildenafil citrate. Biodistribution assays were performed using iodine 123-radiolabeled PnPP-19. In vivo erectile function was evaluated using intracavernosal pressure/main arterial pressure ratio in STZ-diabetic rats after PnPP-19 topical administration.
PnPP-19 may become a new drug able to fill the gap in the pharmacologic treatment of erectile dysfunction, especially for hypertensive and diabetic individuals RESULTS: PnPP-19 potentiated corpus cavernosum relaxation, in both control and SHR rats. SHR-cavernosal tissue treated with PnPP-19 (1-32 Hz) reached the same relaxation levels as control Wistar rats (16 and 32 Hz). PnPP-19 treatment improved cavernosal tissue relaxation in STZ-diabetic mice and rats. PnPP-19 enhanced cGMP levels in STZ-diabetic mice corpus cavernosum strips. After topical or intravenous administration in rats, 123I-PnPP-19 was mainly recruited to the penis. When topically administered (400 μg/rat), PnPP-19 restores erectile function in STZ-diabetic rats, also improving it in healthy rats by increasing the intracavernosal pressure/main arterial pressure ratio. PnPP-19 exhibited an additive effect when co-administered with sildenafil, showing a novel mode of action regardless of phosphodiesterase type 5 inhibition.PnPP-19 seems to be an indicated drug to be tested to treat ED in diabetic and hypertensive patients.PnPP-19, although active by topical application and showing safety to human beings (not shown), has low permeability, about 10% of the applied dose.Our results showed that PnPP-19 may emerge as a potent new drug that can be topically administered, becoming a promising alternative for erectile dysfunction treatment. Nunes da Silva C, Pedrosa Nunes K, De Marco Almeida F, et al. PnPP-19 Peptide Restores Erectile Function In Hypertensive And Diabetic Animals Through Intravenous And Topical Administration. J Sex Med 2019;16:365-374.
PNPP |
|||
HY-15928 | MedChemExpress | 1g | 142.8 EUR |
PNPP |
|||
C6959-1000 | ApexBio | 1g | 50 EUR |
PNPP |
|||
C6959-500 | ApexBio | 500mg | 35 EUR |
PNPP Substrate |
|||
F008-22 | Cygnus Technologies | 22 ml | 216 EUR |
pNPP Substrate |
|||
X156-11ML | Arbor Assays | 11ML | 218 EUR |
pNPP for ELISA |
|||
42R-1005 | Fitzgerald | 500 ml | 424.8 EUR |
PNPP sodium salt |
|||
GX9577-25 | Glentham Life Sciences | 25 | 151.6 EUR |
PNPP sodium salt |
|||
GX9577-5 | Glentham Life Sciences | 5 | 46.6 EUR |
PNPP Liquid Substrate |
|||
F008-100 | Cygnus Technologies | 100 ml | 280.8 EUR |
PNPP Liquid Substrate |
|||
F008-1000 | Cygnus Technologies | 1000 ml | 890.4 EUR |
pNPP Disodium Hexahydrate |
|||
21530110-1 | Bio-WORLD | 1 g | 44.84 EUR |
pNPP Disodium Hexahydrate |
|||
21530110-2 | Bio-WORLD | 5 g | 145.5 EUR |
pNPP Disodium Hexahydrate |
|||
21530110-3 | Bio-WORLD | 25 g | 237.01 EUR |
pNPP Phosphatase Assay Kit |
|||
POPN-01K | BioAssay Systems | 1000 | 408 EUR |
pNPP Phosphatase Assay Kit |
|||
POPN-500 | BioAssay Systems | 500 | 249 EUR |
pNPP Phosphatase Assay Kit |
|||
Z5030009 | Biochain | 500 assays | 213 EUR |
pNPP Phosphatase Assay Kit |
|||
Z5030010 | Biochain | 1,000 assays | 213 EUR |
pNPP-Na (para-Nitrophenylphosphate) |
|||
NB0365 | Bio Basic | 5g | 78.79 EUR |
PNPP sodium salt, 5mg tablets |
|||
GX3711-100EA | Glentham Life Sciences | 100 EA | 302.4 EUR |
PNPP sodium salt, 5mg tablets |
|||
GX3711-100 | Glentham Life Sciences | 100 | 219.7 EUR |
p-Nitrophenyl phosphate (pNPP) substrate 5 mg |
|||
09-2001-100 | Medicago | 5 mg | 237.6 EUR |
p-Nitrophenyl phosphate (pNPP) substrate 5 mg |
|||
09-2001-24 | Medicago | 5 mg | 116.4 EUR |
p-Nitrophenyl phosphate (pNPP) substrate 20 mg |
|||
09-2020-100 | Medicago | 20 mg | 312 EUR |
p-Nitrophenyl phosphate (pNPP) substrate 20 mg |
|||
09-2020-24 | Medicago | 20 mg | 120 EUR |
pNPP [4-Nitrophenyl phosphate, disodium salt] *CAS 4264-83-9* |
|||
11619 | AAT Bioquest | 25 mg | 86 EUR |
pNPP [4-Nitrophenyl phosphate, disodium salt] *CAS 333338-18-4* |
|||
11619-25mg | AAT Bioquest | 25 mg | 86 EUR |
Pnpo/ Rat Pnpo ELISA Kit |
|||
ELI-21651r | Lifescience Market | 96 Tests | 1063.2 EUR |
Pnp2 ORF Vector (Mouse) (pORF) |
|||
ORF054392 | ABM | 1.0 ug DNA | 607.2 EUR |
Pnp2 3'UTR GFP Stable Cell Line |
|||
TU166628 | ABM | 1.0 ml | Ask for price |
Pnpla7/ Rat Pnpla7 ELISA Kit |
|||
ELI-45341r | Lifescience Market | 96 Tests | 1063.2 EUR |